GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (STU:A71) » Definitions » Revenue

Ascendis Pharma AS (STU:A71) Revenue : €363.6 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ascendis Pharma AS Revenue?

Ascendis Pharma AS's revenue for the three months ended in Dec. 2024 was €173.9 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €363.6 Mil. Ascendis Pharma AS's Revenue per Share for the three months ended in Dec. 2024 was €2.91. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €6.23.

Warning Sign:

Ascendis Pharma AS revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Ascendis Pharma AS was 27.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 245.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 117.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 27.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Ascendis Pharma AS's highest 3-Year average Revenue per Share Growth Rate was 245.10% per year. The lowest was -62.40% per year. And the median was 6.45% per year.


Ascendis Pharma AS Revenue Historical Data

The historical data trend for Ascendis Pharma AS's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma AS Revenue Chart

Ascendis Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.95 7.78 51.17 266.72 363.64

Ascendis Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 137.70 95.89 36.00 57.83 173.92

Competitive Comparison of Ascendis Pharma AS's Revenue

For the Biotechnology subindustry, Ascendis Pharma AS's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Revenue distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Revenue falls into.


;
;

Ascendis Pharma AS Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €363.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascendis Pharma AS  (STU:A71) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Ascendis Pharma AS Revenue Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma AS's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma AS Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Ascendis Pharma AS Headlines

No Headlines